peginterferon alfa-2a (Pegasys)

Unknown / undisclosed

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Hepatitis B

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
US
  • PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC); Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB); Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT).
Product first approved 2002FDA label
EU
  • Polycythaemia veraPegasys is indicated as monotherapy in adults for the treatment of polycythaemia vera. Essential thrombocythaemiaPegasys is indicated as monotherapy in adults for the treatment of essential thrombocythaemia..Chronic hepatitis BAdult patientsPegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis (see sections 4.4...
Product first approved 2002EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (50)
Chronic Hepatitis B
NCT01697501 · Hoffmann-La Roche
2012-11-08 – 2013-06-21 · Hepatitis B, Chronic
What this study did
NCT01220596 · Hanyang University
2010-06 – 2013-06 · Hepatitis B, Chronic
What this study did
NCT01892241 · Third Affiliated Hospital, Sun Yat-Sen University
2010-01 – 2013-02 · Antiviral Treatment of Chronic Hepatitis B
What this study did
NCT00154869 · National Taiwan University Hospital
2004-06 – 2007-08 · Hepatitis B, Chronic, Hepatitis C, Chronic
What this study did
NCT00048945 · Hoffmann-La Roche
2002-01 – 2004-10 · Chronic Hepatitis B
What this study did
Other / comorbidity
NCT02201459 · Hospices Civils de Lyon
2014-08 – 2022-10 · Chronic Myeloid Leukemia
What this study did
NCT01387763 · Thomas Stauffer Larsen
2012-01 – 2020-06 · Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis
What this study did
NCT01088659 · Hoffmann-La Roche
2010-02-16 – 2017-12-29 · Hepatitis D, Chronic
What this study did
NCT01259856 · Ronald Hoffman
2011-09 – 2017-06-30 · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
What this study did
NCT03020082 · Ascletis Pharmaceuticals Co., Ltd.
2016-06 – 2017-05 · Chronic Hepatitis C
What this study did
NCT01718301 · Anna Cruceta
2013-03-10 – 2015-06-30 · Hepatitis C, HIV Infections, COINFECTION
What this study did
NCT01544920 · Merck Sharp & Dohme LLC
2012-05-30 – 2015-05-19 · Hepatitis C, Chronic
What this study did
NCT01598090 · Bristol-Myers Squibb
2012-06-14 – 2015-05-15 · Hepatitis C Virus
What this study did
NCT01753557 · Tanabe Pharma Corporation
2012-12 – 2014-11 · Chronic Hepatitis C (CHC)
What this study did
NCT01446250 · Debiopharm International SA
2011-12 – 2013-05 · Hepatitis C
What this study did
NCT01292239 · Janssen Pharmaceutical K.K.
2011-02 – 2012-10 · Hepatitis C, Chronic
What this study did
NCT01288209 · Janssen Pharmaceutical K.K.
2011-02 – 2012-09 · Hepatitis C, Chronic
What this study did
NCT01500772 · Debiopharm International SA
2012-03 – 2012-05 · Hepatitis C
What this study did
NCT02736721 · Hoffmann-La Roche
2003-09 – 2010-11 · Myelogenous Leukemia, Chronic
What this study did
NCT00304551 · Chugai Pharmaceutical
2006-06 – 2010-06 · Liver Cirrhosis, Chronic Hepatitis C
What this study did
NCT00006164 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2000-06 – 2009-10 · Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
What this study did
NCT00336518 · Májbetegekért Alapítvány
2006-06 – 2009-07 · Chronic Hepatitis C
What this study did
NCT02762383 · Hoffmann-La Roche
2005-03 – 2009-06 · HIV/HCV Coinfection
What this study did
NCT00122616 · French National Agency for Research on AIDS and Viral Hepatitis
2003-11 – 2009-03 · HIV Infections, Hepatitis C, Chronic
What this study did
NCT02732639 · Hoffmann-La Roche
2005-10 – 2008-12 · Hepatitis D, Chronic
What this study did
NCT00136318 · Charite University, Berlin, Germany
2004-01 – 2008-09 · Depression
What this study did
NCT02791256 · Hoffmann-La Roche
2005-06 – 2008-06 · Hepatitis C, Chronic
What this study did
NCT00039962 · SciClone Pharmaceuticals
started 2002-05 · Hepatitis C, Hepatitis C, Chronic
What this study did
NCT00040027 · SciClone Pharmaceuticals
started 2002-04 · Hepatitis C, Hepatitis C, Chronic
What this study did
NCT02806505 · Hoffmann-La Roche
2004-06 – 2007-08 · Hepatitis C, Chronic
What this study did
NCT00299923 · University of Hamburg-Eppendorf
started 2005-11 · Hepatitis C, Chronic, Relapse
What this study did
NCT00466219 · University Hospital, Geneva
2002-05 – 2006-12 · Hepatitis C
What this study did
NCT00381953 · Foundation for Liver Research
2003-02 – 2006-07 · Hepatitis C
What this study did
NCT00038974 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2002-08 – 2005-11 · Hepatitis C
What this study did
NCT00144469 · Chugai Pharmaceutical
2002-05 – 2005-03 · Chronic Hepatitis C
What this study did
NCT00221624 · University Hospital, Bordeaux
2001-11 – 2004-04 · HCV Infection, Hepatitis C, Chronic
What this study did
Phase 2/3 (5)
Chronic Hepatitis B
NCT02992704 · Seng Gee Lim
2016-08 – 2020-01 · Chronic Hepatitis, B Virus, Carrier of Viral Hepatitis Type B
What this study did
NCT00391638 · French National Agency for Research on AIDS and Viral Hepatitis
2007-01 – 2012-10 · Hepatitis B, HIV Infections
What this study did
Other / comorbidity
NCT01890772 · Timothy Morgan, MD
2013-08 – 2015-10 · Hepatitis C
What this study did
NCT00421434 · Romark Laboratories L.C.
2006-06 – 2008-09 · Chronic Hepatitis C
What this study did
NCT02829775 · Hoffmann-La Roche
2004-01 – 2008-01 · Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma
What this study did
Phase 2 (65)
Chronic Hepatitis B
NCT06092333 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2025-01-31 – 2028-08-31 · Chronic Hepatitis B
What this study did
NCT04980482 · Arbutus Biopharma Corporation
2021-10-29 – 2025-05-21 · Chronic Hepatitis b
What this study did
NCT00051077 · National Institute of Allergy and Infectious Diseases (NIAID)
— · HIV Infections, Hepatitis B, Hepatitis C
What this study did
NCT02565719 · Replicor Inc.
2016-03 – 2019-05 · Chronic Hepatitis B
What this study did
NCT03125213 · Alios Biopharma Inc.
2017-09-12 – 2019-02-15 · Hepatitis B, Chronic
What this study did
NCT02364336 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2015-02-14 – 2018-05-21 · Chronic Hepatitis B
What this study did
NCT02233075 · Replicor Inc.
2014-09 – 2017-05 · Chronic HBV Infection (HBeAg Negative)
What this study did
NCT02726789 · Replicor Inc.
2012-10 – 2016-12 · Hepatitis B, Chronic
What this study did
NCT00442572 · Hoffmann-La Roche
2006-07-03 – 2012-04-23 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT04798612 · Zealand University Hospital
2023-08-14 – 2025-12-01 · Colon Cancer
What this study did
NCT05941845 · Centre Hospitalier Universitaire de Nice
2023-09-14 – 2025-09-14 · Membranous Nephropathy
What this study did
NCT00452023 · M.D. Anderson Cancer Center
2005-04-07 – 2023-05-26 · Myeloproliferative Disorders
What this study did
NCT02816684 · University of Central Florida
2016-06 – 2018-08 · Anxiety Disorders
What this study did
NCT02430194 · EIT Pharma, Inc.
2014-12 – 2017-06-15 · Chronic Hepatitis D Infection
What this study did
NCT01758588 · Weill Medical College of Cornell University
2013-01 – 2017-06 · Myelofibrosis
What this study did
NCT03020004 · Ascletis Pharmaceuticals Co., Ltd.
2016-01 – 2017-02 · Chronic Hepatitis C
What this study did
NCT01259817 · Ronald Hoffman
2011-09 – 2016-12 · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
What this study did
NCT02430181 · EIT Pharma, Inc.
2014-11 – 2015-11 · Chronic Hepatitis D Infection
What this study did
NCT01428063 · Bristol-Myers Squibb
2011-09 – 2014-12 · Hepatitis C Virus Infection
What this study did
NCT01371604 · Merck Sharp & Dohme LLC
2011-07 – 2014-10 · Hepatitis C, Chronic
What this study did
NCT01725542 · ANRS, Emerging Infectious Diseases
2012-12 – 2014-06 · HCV-HIV Co-Infection
What this study did
NCT01392170 · M.D. Anderson Cancer Center
2011-10 – 2014-03 · Leukemia
What this study did
NCT01516918 · Vertex Pharmaceuticals Incorporated
2012-02 – 2013-12 · Chronic Hepatitis C Virus
What this study did
NCT01080222 · Vertex Pharmaceuticals Incorporated
2010-08 – 2013-11 · Chronic Hepatitis C Virus Infection
What this study did
NCT01356160 · Gilead Sciences
2011-07 – 2013-06 · Hepatitis C, Chronic
What this study did
NCT01331850 · Hoffmann-La Roche
2011-05 – 2013-01 · Hepatitis C, Chronic
What this study did
NCT00892697 · Weill Medical College of Cornell University
2009-05 – 2012-12 · Hepatitis C
What this study did
NCT01170962 · Bristol-Myers Squibb
2010-08 – 2012-12 · Hepatitis C Virus
What this study did
NCT01030432 · Bristol-Myers Squibb
2010-02 – 2012-10 · Hepatitis C Virus
What this study did
NCT01215643 · Debiopharm International SA
2010-10 – 2012-05 · Hepatitis C, Chronic Pain
What this study did
NCT01057667 · Hoffmann-La Roche
2010-02 – 2012-04 · Hepatitis C, Chronic
What this study did
NCT00983853 · Vertex Pharmaceuticals Incorporated
2009-10 – 2012-03 · Hepatitis C, HIV Infections
What this study did
NCT00869661 · Hoffmann-La Roche
2001-02 – 2012-02 · Hepatitis C, Chronic
What this study did
NCT01265511 · Scynexis, Inc.
2010-11 – 2011-10 · Hepatitis C Infection
What this study did
NCT00475176 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2007-05 – 2011-05 · Chronic Hepatitis C
What this study did
NCT00996476 · Janssen Pharmaceutical K.K.
2009-07 – 2011-01 · Hepatitis C, Chronic
What this study did
NCT01011166 · Merck Sharp & Dohme LLC
2009-11 – 2010-07 · Chronic Hepatitis C Infection
What this study did
NCT00495391 · Romark Laboratories L.C.
2007-07 – 2010-02 · Chronic Hepatitis C
What this study did
Phase 1/2 (6)
Chronic Hepatitis B
NCT03109730 · Assembly Biosciences
2017-06-15 – 2018-06-12 · Chronic Hepatitis B
What this study did
NCT02646189 · Replicor Inc.
2011-08 – 2013-08 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT07288112 · Diakonos Oncology Corporation
2026-04-06 – 2033-01 · Refractory Melanoma
What this study did
NCT02328755 · University of Michigan Rogel Cancer Center
2015-01 – 2019-03-25 · Acute Myeloid Leukemia
What this study did
NCT00911963 · Vertex Pharmaceuticals Incorporated
2009-04 – 2012-09 · Hepatitis C
What this study did
NCT00962715 · M.D. Anderson Cancer Center
started 2011-04 · Chronic Lymphocytic Leukemia
What this study did
Phase 1 (14)
Chronic Hepatitis B
NCT07389044 · IntegerBio
2026-02-20 – 2027-07-01 · Chronic Hepatitis B Virus Infection
What this study did
NCT02908191 · Assembly Biosciences
2016-11 – 2018-06-12 · Chronic Hepatitis B
What this study did
NCT02401737 · Novira Therapeutics, Inc.
2015-01-31 – 2016-05-18 · Chronic Hepatitis B
What this study did
NCT02112799 · Novira Therapeutics, Inc.
2014-04-30 – 2016-05-18 · Chronic Hepatitis B
What this study did
NCT00962975 · Hoffmann-La Roche
2009-09 – 2013-05 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT02407080 · John Mascarenhas
2015-04 – 2018-12-19 · Polycythemia Vera, Essential Thrombocythemia
What this study did
NCT01185860 · Hoffmann-La Roche
2009-08 – 2012-01 · Hepatitis C, Chronic
What this study did
NCT01343186 · Xiamen Amoytop Biotech Co., Ltd.
2011-01 – 2011-11 · Healthy Subjects
What this study did
NCT01889849 · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
2010-10 – 2011-08 · Chronic Viral Hepatitis C
What this study did
NCT01087944 · Hoffmann-La Roche
2010-03 – 2010-06 · Hepatitis C, Chronic
What this study did
Phase 4 (96)
Chronic Hepatitis B
NCT03084250 · Shanghai Nanhui Nanhua Hospital
2017-03-10 – 2023-12-01 · Hepatitis B
What this study did
NCT03013556 · Ruijin Hospital
2016-11 – 2021-12-31 · Chronic Hepatitis
What this study did
NCT03253250 · Huashan Hospital
2017-09-01 – 2019-12 · Chronic Hepatitis b, Hepatic Carcinoma
What this study did
NCT01373684 · Foundation for Liver Research
2012-05-25 – 2019-10-28 · Chronic Hepatitis B
What this study did
NCT01925820 · National Taiwan University Hospital
2013-01 – 2018-12 · Chronic Hepatitis B
What this study did
NCT02894918 · Henan Provincial People's Hospital
2016-09 – 2018-12 · Chronic Hepatitis B
What this study did
NCT02097004 · Seoul National University Hospital
2014-04 – 2018-03-13 · Hepatitis B, Chronic
What this study did
NCT02474316 · Ruijin Hospital
2014-08 – 2017-12 · Chronic Hepatitis B
What this study did
NCT03209011 · Yao Xie
2016-01 – 2017-12 · Chronic Hepatitis B Infection
What this study did
NCT03208998 · Beijing Ditan Hospital
2016-01 – 2017-12 · Chronic Hepatitis B Infection
What this study did
NCT03209037 · Beijing Ditan Hospital
2016-01 – 2017-12 · Chronic Hepatitis B Infection
What this study did
NCT02560649 · Ruijin Hospital
2015-05 – 2017-02 · Chronic Hepatitis B
What this study did
NCT02822547 · Yonsei University
2015-03 – 2016-12 · Chronic Hepatitis B
What this study did
NCT01456312 · Gangnam Severance Hospital
2012-09 – 2016-08 · Hepatitis B, Chronic
What this study did
NCT01906580 · Beijing 302 Hospital
2011-07 – 2016-07 · Chronic Hepatitis B
What this study did
NCT00597259 · National Taiwan University Hospital
2008-01 – 2014-02 · Chronic Hepatitis B
What this study did
NCT00921180 · National Taiwan University Hospital
2007-02 – 2013-12 · Hepatitis B, Chronic
What this study did
NCT00917761 · National Taiwan University Hospital
2007-02 – 2013-12 · Hepatitis B, Chronic
What this study did
NCT00877760 · Foundation for Liver Research
2009-08 – 2013-07 · Chronic Hepatitis B
What this study did
NCT01086085 · Hoffmann-La Roche
2010-04 – 2013-03 · Hepatitis B, Chronic
What this study did
NCT00940485 · Hoffmann-La Roche
2009-04 – 2011-12 · Hepatitis B, Chronic
What this study did
NCT00435825 · Hoffmann-La Roche
2007-03 – 2010-12 · Hepatitis B, Chronic
What this study did
NCT00436163 · Hoffmann-La Roche
2007-03 – 2010-05 · Hepatitis B, Chronic
What this study did
NCT00487747 · Hoffmann-La Roche
2006-08 – 2009-10 · Hepatitis B, Chronic
What this study did
NCT01787279 · Hoffmann-La Roche
2006-01 – 2009-05 · Hepatitis B, Chronic
What this study did
NCT02791269 · Hoffmann-La Roche
2006-01 – 2008-07 · Hepatitis B, Chronic
What this study did
NCT00460850 · Hoffmann-La Roche
2007-09 – 2008-06 · Hepatitis B, Chronic
What this study did
NCT01519921 · Hoffmann-La Roche
2005-10 – 2008-06 · Hepatitis B, Chronic
What this study did
NCT00226382 · Chinese University of Hong Kong
2005-01 – 2008-04 · Chronic Hepatitis B
What this study did
NCT02570191 · Hoffmann-La Roche
2004-11 – 2007-02 · Hepatitis B, Chronic
What this study did
NCT02604823 · Hoffmann-La Roche
2003-11 – 2005-11 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT01937728 · Kaohsiung Medical University Chung-Ho Memorial Hospital
2010-03 – 2016-12 · Hepatitis C
What this study did
NCT01336010 · Kirby Institute
2011-08 – 2015-06 · Acute Hepatitis C
What this study did
NCT01592006 · University of Chicago
2012-04 – 2014-09 · Hepatitis C
What this study did
NCT02601976 · Getz Pharma
2010-08 – 2014-09 · Hepatitis C
What this study did
NCT01591460 · Hoffmann-La Roche
2012-08 – 2014-06 · Hepatitis C, Chronic
What this study did
NCT00532701 · National Taiwan University Hospital
2007-11 – 2014-03 · Chronic Hepatitis C
What this study did
NCT02641379 · Hoffmann-La Roche
2003-05 – 2013-11 · Hepatitis C, Chronic
What this study did
NCT00491244 · National Taiwan University Hospital
2007-06 – 2013-09 · Chronic Hepatitis C
What this study did
NCT06922643 · Nanogen Pharmaceutical Biotechnology Joint Stock Company
2011-03-01 – 2013-03-01 · Chronic Hepatitis C
What this study did
NCT01056172 · Pusan National University Yangsan Hospital
2010-01 – 2012-12 · Chronic Hepatitis C
What this study did
NCT01378104 · The Catholic University of Korea
2008-10 – 2012-09 · Sustained Virologic Response, IL28B Polymorphism
What this study did
NCT00922779 · Hoffmann-La Roche
2002-06 – 2012-06 · Hepatitis C, Chronic
What this study did
Early phase / not applicable (9)
Chronic Hepatitis B
NCT03919565 · Third Affiliated Hospital, Sun Yat-Sen University
2019-02-01 – 2021-12-31 · Hepatitis B, Liver Fibrosis
What this study did
NCT03920605 · Third Affiliated Hospital, Sun Yat-Sen University
2019-02-01 – 2021-12-31 · Hepatitis B, Liver Fibrosis
What this study did
NCT03210493 · Beijing Ditan Hospital
2016-01 – 2017-12 · Chronic Hepatitis B Infection
What this study did
NCT03210506 · Beijing Ditan Hospital
2016-01 – 2017-12 · Chronic Hepatitis B Infection
What this study did
NCT01464281 · The Second Affiliated Hospital of Chongqing Medical University
2011-10 – 2016-12 · Chronic Hepatitis B
What this study did
NCT01599130 · Sun Yat-sen University
2012-07 – 2014-04 · Hepatitis B
What this study did
NCT00188240 · University Health Network, Toronto
started 2003-08 · Hepatitis C, Hepatitis B
What this study did
Other / comorbidity
NCT01639547 · Chang Gung Memorial Hospital
2012-07 – 2014-07 · Chronic Hepatitis C
What this study did
NCT00909129 · Karolinska Institutet
— · Human Immunodeficiency Virus, Chronic Hepatitis C
What this study did
Used as active comparator (25)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (10)
Chronic Hepatitis B
NCT01760122 · Xiamen Amoytop Biotech Co., Ltd.
2013-03 – 2015-08 · Chronic Hepatitis B
What this study did
Other / comorbidity
NCT01889433 · Biocad
2013-07-10 – 2015-12-02 · Hepatitis, Hepatitis C
What this study did
NCT01903278 · Beijing Kawin Technology Share-Holding Co., Ltd.
2013-06 – 2015-08 · Chronic Hepatitis c
What this study did
NCT01754974 · Bristol-Myers Squibb
2013-03 – 2014-09 · Hepatitis C Virus (HCV)
What this study did
NCT01581398 · Xiamen Amoytop Biotech Co., Ltd.
2012-04 – 2014-06 · Chronic Hepatitis C
What this study did
NCT00402428 · Human Genome Sciences Inc.
2006-12 – 2009-02 · Chronic Hepatitis C
What this study did
NCT00411385 · Human Genome Sciences Inc.
2007-02 – 2008-10 · Chronic Hepatitis C
What this study did
NCT00081770 · Merck Sharp & Dohme LLC
2004-03 – 2007-11 · Hepatitis C, Chronic
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT01623336 · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
2012-01 – 2016-12 · Chronic Hepatitis C
What this study did
Phase 2 (7)
Chronic Hepatitis B
NCT02888106 · Hepatera Ltd.
2016-04 – 2020-10-30 · Chronic Viral Hepatitis B With Delta-agent
What this study did
NCT01143662 · Xiamen Amoytop Biotech Co., Ltd.
2010-07 – 2012-04 · Chronic Hepatitis B
What this study did
Other / comorbidity
NCT03852433 · Gilead Sciences
2019-05-31 – 2022-09-28 · Chronic Hepatitis Delta
What this study did
NCT01587586 · PharmaEssentia
2011-10-18 – 2016-11-22 · Hepatitis C, Chronic
What this study did
NCT01908335 · Beijing Kawin Technology Share-Holding Co., Ltd.
2012-10 – 2014-07 · Chronic Hepatitis C
What this study did
NCT01001754 · ZymoGenetics
2010-05 – 2012-05 · Hepatitis C, Chronic
What this study did
NCT01140997 · Xiamen Amoytop Biotech Co., Ltd.
2010-07 – 2012-03 · Chronic Hepatitis C
What this study did
Phase 1/2 (5)
Chronic Hepatitis B
NCT03294798 · Tianjin SinoBiotech Ltd.
2017-06-13 – 2021-03-15 · Hepatitis B Virus
What this study did
NCT01997944 · Beijing Bio-Fortune Ltd.
2013-11 – 2014-11 · Chronic Hepatitis B
What this study did
NCT00964665 · Novartis Pharmaceuticals
2009-07 – 2010-11 · Chronic Hepatitis B
What this study did
Other / comorbidity
NCT02057887 · Hanmi Pharmaceutical Company Limited
2013-07 – 2014-08 · Chronic Hepatitis C Virus Genotype I
What this study did
NCT01194037 · HanAll BioPharma Co., Ltd.
2011-06-23 – 2011-11-28 · Chronic Hepatitis C Infection, Genotype 1
What this study did
Phase 1 (2)
Other / comorbidity
NCT01504581 · Hanmi Pharmaceutical Company Limited
2011-03 – 2011-09 · Healthy
What this study did
NCT05129644 · PharmaEssentia
2009-11-07 – 2010-06-26 · Healthy Volunteers
What this study did
Appears in other studies (18)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Chronic Hepatitis B
NCT00661076 · Hoffmann-La Roche
2008-08 – 2011-05 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT01890200 · TCM Biotech International Corp.
2015-06 – 2018-06 · Chronic Hepatitis C
What this study did
NCT01318694 · Debiopharm International SA
2011-03 – 2013-08 · Hepatitis C
What this study did
NCT00627926 · Vertex Pharmaceuticals Incorporated
2008-03 – 2010-05 · Hepatitis C
What this study did
Phase 2 (9)
Other / comorbidity
NCT01482390 · Hoffmann-La Roche
2011-11-30 – 2014-01-31 · Hepatitis C
What this study did
NCT01482403 · Hoffmann-La Roche
2011-11 – 2014-01 · Hepatitis C, Chronic
What this study did
NCT01903954 · Hoffmann-La Roche
2011-01 – 2013-05 · Hepatitis C, Chronic
What this study did
NCT00963885 · Hoffmann-La Roche
2009-08 – 2012-01 · Hepatitis C, Chronic
What this study did
NCT01017575 · Bristol-Myers Squibb
2009-12 – 2011-10 · Hepatitis C Infection
What this study did
NCT00556504 · TCM Biotech International Corp.
2007-07 – 2011-05 · Chronic Hepatitis C
What this study did
NCT01142700 · Bristol-Myers Squibb
2010-07 – 2010-12 · Chronic Hepatitis C Virus Genotype 1
What this study did
NCT00637923 · Romark Laboratories L.C.
2008-03 – 2010-04 · Chronic Hepatitis C
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02637999 · Hepatera Ltd.
2014-02-13 – 2016-01-21 · Chronic Hepatitis D Infection
What this study did
Phase 4 (3)
Chronic Hepatitis B
NCT01179594 · Hoffmann-La Roche
2010-09-18 – 2014-11 · Hepatitis B, Chronic
What this study did
NCT00922207 · Hoffmann-La Roche
2010-05-07 – 2014-09-29 · Hepatitis B, Chronic
What this study did
NCT00614471 · Hoffmann-La Roche
2007-08 – 2009-10 · Hepatitis B, Chronic
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Hepatitis B: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Peginterferon Alfa-2a (Pegasys): this drugApproved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Interferon Beta-1b
Approved(overall)
Biologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Beta-1a (Plegridy)
Approved(overall)
Biologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Rebif (interferon Beta 1a)
Approved(overall)
Biologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Ropeginterferon Alfa-2b (Besremi)
Approved(overall)
Protein / enzyme therapeuticType I interferon receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Interferon-Beta1
—(overall)
Biologic (subtype unspecified)Type I interferon receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow peginterferon alfa-2a (Pegasys) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 1Chronic Hepatitis BRecruiting
Est. primary completion 2027-04-30 · NCT07389044 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 2Chronic Hepatitis BActive not recruiting
Est. primary completion 2028-02-29 · NCT06092333 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 1/2Refractory MelanomaRecruiting
Est. primary completion 2031-01 · NCT07288112 · CT.gov ↗
What to watch

See the full readout calendar ↗